Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Full Medtronic Results Offer Little Reason For Optimism On Renal Denervation

This article was originally published in The Gray Sheet

Executive Summary

Renal denervation did not have a significant effect on systolic blood pressure in the SYMPLICITY HTN-3 trial, the first major sham-controlled trial of renal denervation for drug-resistant hypertension. The trial’s sponsor, Medtronic, had previously announced that it missed its primary endpoint but full results of the study were presented for the first time at the ACC meeting in Washington, DC on March 29.

You may also be interested in...



Renal Denervation Story Not Over Yet Despite SYMPLICITY HTN-3 Disappointment

Even though the first major sham-controlled trial showed no benefit for renal denervation in treating hypertension, statements provided by companies developing the technology suggest they are not giving up on it yet.

Future Of Renal Denervation On Trial At ACC 2014 This Weekend

The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.

Covidien Quits Renal Denervation Race; Others Stick It Out, For Now

A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel